This article explores methods to enhance efficiency in the drug discovery and development pipeline, focusing on optimizing ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven <a target=_ ...

Biomedical engineers at Duke University have developed an AI-based platform that designs short proteins, termed peptides, ...

If your genes could set an alarm clock, EZH1 might be the one ringing the bell. A new study has revealed how this ...

The peptide Palmitoyl-GHK (Pal-GHK) has garnered considerable attention in the scientific community due to its structural attributes and potential functional roles in biological research and cellular ...

Employers need to “walk the talk” to create a healthy workplace culture that prevents and reduces obesity and lowers health ...

In partnership with OPKO Health (Nasdaq: “OPK”), Entera is also developing the first oral oxyntomodulin, a dual targeted GLP-1/glucagon peptide tablet for the treatment of obesity, fibrotic ...

Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase promoting complex/cyclosome (APC/C) that is essential in mitosis and ...

CEO Miranda Toledano will provide a business overview and update. Entera is focused on developing orally delivered peptide and protein therapies for significant unmet medical needs, leveraging its ...

New research shows that loose or sagging skin on the face and neck is most often noted after medication-driven weight loss, with facial changes ...